Featured Research

from universities, journals, and other organizations

Antiviral therapy can prevent liver cancer in chronic hepatitis B patients

Date:
June 23, 2014
Source:
American Gastroenterological Association
Summary:
One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. Two new studies provide strong evidence that antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection.

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year. Two new studies appearing in the June issue of Gastroenterology provide strong evidence that antiviral therapy can reduce the risk of liver cancer in patients with chronic hepatitis B infection. Gastroenterology is the official journal of the American Gastroenterological Association.

Related Articles


In the first paper,1 researchers from National Yang-Ming University in Taiwan showed that the licensed oral antiviral agent nucleos(t)ide (NUC) resulted in a reduced long-term risk for liver cancer in a large, nationwide cohort of chronic hepatitis B patients. This retrospective study analyzed the risk of hepatocellular carcinoma, the most common form of liver cancer, in patients treated with several different agents. The NUC-treated cohort had a significantly lower seven-year incidence of liver cancer compared with controls. Overall, the effect of the treatment on reduced risk for cancer was stronger in young patients without cirrhosis and in patients without diabetes.

"Our findings suggest that NUC use reduces the risk of liver cancer in chronic hepatitis B patients, particularly in younger patients with minimal liver damage," said lead study author Chun-Ying Wu, MD, PhD. "The large cohort contributed to the strength of our study, leading to reliable results regarding who can benefit the most from this treatment."

The second study,2 also a retrospective analysis, compared outcomes of chronic hepatitis B patients treated with the antiviral agent entecavir and a less potent drug, lamivudine, at a tertiary care hospital in Seoul, Korea. Researchers found that patients in the entecavir group had a significantly lower risk of death or transplantation than patients treated with lamivudine; however this reduction in risk did not translate to a decreased risk of liver cancer. Both groups produced a similar reduction in liver cancer.

"There is a persistent risk of liver cancer in hepatitis B patients treated with even the most potent agents," said study author Young-Suk Lim, MD, PhD, from department of gastroenterology, University of Ulsan College of Medicine, Seoul, Korea. "Based on our findings, we support recommendations that surveillance for liver cancer should be continued in chronic hepatitis B patients regardless of the treatment used."

Both papers support the accumulating evidence that, to avert the risk of liver cancer, antiviral therapy needs to be initiated early during the chronic hepatitis B infection, preferably before the stage of advanced fibrosis.


Story Source:

The above story is based on materials provided by American Gastroenterological Association. Note: Materials may be edited for content and length.


Journal References:

  1. Chun-Ying Wu, Jaw-Town Lin, Hsiu J. Ho, Chien-Wei Su, Teng-Yu Lee, Shen-Yung Wang, Chuhui Wu, Jaw-Ching Wu. Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study. Gastroenterology, 2014; 147 (1): 143 DOI: 10.1053/j.gastro.2014.03.048
  2. Young–Suk Lim, Seungbong Han, Nae–Yun Heo, Ju Hyun Shim, Han Chu Lee, Dong Jin Suh. Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. Gastroenterology, 2014; 147 (1): 152 DOI: 10.1053/j.gastro.2014.02.033

Cite This Page:

American Gastroenterological Association. "Antiviral therapy can prevent liver cancer in chronic hepatitis B patients." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623155059.htm>.
American Gastroenterological Association. (2014, June 23). Antiviral therapy can prevent liver cancer in chronic hepatitis B patients. ScienceDaily. Retrieved December 22, 2014 from www.sciencedaily.com/releases/2014/06/140623155059.htm
American Gastroenterological Association. "Antiviral therapy can prevent liver cancer in chronic hepatitis B patients." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623155059.htm (accessed December 22, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, December 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Touch-Free Smart Phone Empowers Mobility-Impaired

Touch-Free Smart Phone Empowers Mobility-Impaired

Reuters - Innovations Video Online (Dec. 21, 2014) A touch-free phone developed in Israel enables the mobility-impaired to operate smart phones with just a movement of the head. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Earthworms Provide Cancer-Fighting Bacteria

Earthworms Provide Cancer-Fighting Bacteria

Reuters - Innovations Video Online (Dec. 21, 2014) Polish scientists isolate bacteria from earthworm intestines which they say may be used in antibiotics and cancer treatments. Suzannah Butcher reports. Video provided by Reuters
Powered by NewsLook.com
Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Existing Chemical Compounds Could Revive Failing Antibiotics, Says Danish Scientist

Reuters - Innovations Video Online (Dec. 21, 2014) A team of scientists led by Danish chemist Jorn Christensen says they have isolated two chemical compounds within an existing antipsychotic medication that could be used to help a range of failing antibiotics work against killer bacterial infections, such as Tuberculosis. Jim Drury went to meet him. Video provided by Reuters
Powered by NewsLook.com
Hugging It Out Could Help You Ward Off A Cold

Hugging It Out Could Help You Ward Off A Cold

Newsy (Dec. 21, 2014) Carnegie Mellon researchers found frequent hugs can help people avoid stress-related illnesses. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins